{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:42:24Z","timestamp":1790840544475,"version":"4.1.0"},"reference-count":60,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"9","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA-72999"],"award-info":[{"award-number":["R01CA-72999"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RO1CA-77776"],"award-info":[{"award-number":["RO1CA-77776"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2018,9,7]]},"abstract":"<jats:p>A novel mTOR complex assembled by the ETS transcription factor ETV7 contributes to rapamycin resistance in cancer.<\/jats:p>","DOI":"10.1126\/sciadv.aar3938","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T18:06:08Z","timestamp":1536775568000},"source":"Crossref","is-referenced-by-count":106,"title":["ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer"],"prefix":"10.1126","volume":"4","author":[{"given":"Franklin C.","family":"Harwood","sequence":"first","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon I.","family":"Klein Geltink","sequence":"additional","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan P.","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cardone","sequence":"additional","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Janke","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-1274","authenticated-orcid":true,"given":"Igor","family":"Entin","sequence":"additional","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-334X","authenticated-orcid":true,"given":"Leena","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Houghton","sequence":"additional","affiliation":[{"name":"Greehey Children\u2019s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard C.","family":"Grosveld","sequence":"additional","affiliation":[{"name":"Department of Genetics, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2010.271"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.014"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa3870"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11016"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12122"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1751"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20090489"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M900301200"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0881"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187532"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12688\/f1000research.1-4.v1","article-title":"Rapamycin-insensitive mTORC1 activity controls eIF4E:4E-BP1 binding","volume":"1","author":"Livingstone M.","year":"2012","unstructured":"M. Livingstone, M. Bidinosti, Rapamycin-insensitive mTORC1 activity controls eIF4E:4E-BP1 binding. F1000Res. 1, 4 (2012).","journal-title":"F1000Res."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2008-10-184515","article-title":"Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia","volume":"114","author":"Tamburini J.","year":"2009","unstructured":"J. Tamburini, A. S. Green, V. Bardet, N. Chapuis, S. Park, L. Willems, M. Uzunov, N. Ifrah, F. Dreyfus, C. Lacombe, P. Mayeux, D. Bouscary, Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114, 1618\u20131627 (2009).","journal-title":"Blood"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3341.011k44_3341_3348"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/MCB.25.6.2395-2405.2005","article-title":"The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis","volume":"25","author":"Cardone M.","year":"2005","unstructured":"M. Cardone, A. Kandilci, C. Carella, J. A. Nilsson, J. A. Brennan, S. Sirma, U. Ozbek, K. Boyd, J. L. Cleveland, G. C. Grosveld, The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol. Cell. Biol. 25, 2395\u20132405 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2005-03-1196","article-title":"The ETS factor TEL2 is a hematopoietic oncoprotein","volume":"107","author":"Carella C.","year":"2006","unstructured":"C. Carella, M. Potter, J. Bonten, J. E. Rehg, G. Neale, G. C. Grosveld, The ETS factor TEL2 is a hematopoietic oncoprotein. Blood 107, 1124\u20131132 (2006).","journal-title":"Blood"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0839"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1154"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0338"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/1078-0432.CCR-07-5090","article-title":"Molecular characterization of the pediatric preclinical testing panel","volume":"14","author":"Neale G.","year":"2008","unstructured":"G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, J. Khoury, T. J. Triche, R. C. Seeger, R. Gilbertson, J. Khan, M. A. Smith, P. J. Houghton, Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res. 14, 4572\u20134583 (2008).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4974"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jss.2008.06.008","article-title":"A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States","volume":"155","author":"Matos J. M.","year":"2009","unstructured":"J. M. Matos, F. A. Witzmann, O. W. Cummings, C. M. Schmidt, A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J. Surg. Res. 155, 237\u2013243 (2009).","journal-title":"J. Surg. Res."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"26329","DOI":"10.1074\/jbc.271.42.26329","article-title":"Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase","volume":"271","author":"Chen H.-C.","year":"1996","unstructured":"H.-C. Chen, P. A. Appeddu, H. Isoda, J.-L. Guan, Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J. Biol. Chem. 271, 26329\u201326334 (1996).","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501707200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.3.1871"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/MCB.21.3.743-754.2001","article-title":"The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells","volume":"21","author":"Scheper G. C.","year":"2001","unstructured":"G. C. Scheper, N. A. Morrice, M. Kleijn, C. G. Proud, The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol. Cell. Biol. 21, 743\u2013754 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/emboj\/18.1.270","article-title":"Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E","volume":"18","author":"Pyronnet S.","year":"1999","unstructured":"S. Pyronnet, H. Imataka, A.-C. Gingras, R. Fukunaga, T. Hunter, N. Sonenberg, Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. EMBO J. 18, 270\u2013279 (1999).","journal-title":"EMBO J."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.2870050313","article-title":"Translocations involving 12p in acute myeloid leukemia: Association with prior myelodysplasia and exposure to mutagenic agents","volume":"5","author":"United Kingdom Cancer Cytogenetics Group (UKCCG)","year":"1992","unstructured":"United Kingdom Cancer Cytogenetics Group (UKCCG), Translocations involving 12p in acute myeloid leukemia: Association with prior myelodysplasia and exposure to mutagenic agents. Genes Chromosomes Cancer 5, 252\u2013254 (1992).","journal-title":"Genes Chromosomes Cancer"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aad8463"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.04.004"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1199484"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2925"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C200665200"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.15.4173"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.79.081507.103945"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500125200"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/onc.2013.113","article-title":"Glycogen synthase kinase-3\u03b2 positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1","volume":"33","author":"Shin S.","year":"2014","unstructured":"S. Shin, L. Wolgamott, J. Tcherkezian, S. Vallabhapurapu, Y. Yu, P. P. Roux, S.-O. Yoon, Glycogen synthase kinase-3\u03b2 positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690\u20131699 (2014).","journal-title":"Oncogene"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/378785a0"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2007-02-071258","article-title":"The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling","volume":"110","author":"Staber P. B.","year":"2007","unstructured":"P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, W. G. Dirks, V. Sexl, H. Bergler, M. E. Kadin, D. W. Sternberg, L. Kenner, G. Hoefler, The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling. Blood 110, 3374\u20133383 (2007).","journal-title":"Blood"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/acel.12313","article-title":"Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins","volume":"14","author":"Schreiber K. H.","year":"2015","unstructured":"K. H. Schreiber, D. Ortiz, E. C. Academia, A. C. Anies, C.-Y. Liao, B. K. Kennedy, Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 14, 265\u2013273 (2015).","journal-title":"Aging Cell"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/jcp.24065","article-title":"PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics","volume":"227","author":"Mahajan K.","year":"2012","unstructured":"K. Mahajan, N. P. Mahajan, PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics. J. Cell. Physiol. 227, 3178\u20133184 (2012).","journal-title":"J. Cell. Physiol."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2004.06.054"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5329.1109"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00183"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-10-3126","article-title":"Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1\/mTORC2 inhibitors","volume":"71","author":"Falcon B. L.","year":"2011","unstructured":"B. L. Falcon, S. Barr, P. C. Gokhale, J. Chou, J. Fogarty, P. Depeille, M. Miglarese, D. M. Epstein, D. M. McDonald, Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1\/mTORC2 inhibitors. Cancer Res. 71, 1573\u20131583 (2011).","journal-title":"Cancer Res."},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"e47741","DOI":"10.1371\/journal.pone.0047741","article-title":"Conditional astroglial Rictor overexpression induces malignant glioma in mice","volume":"7","author":"Bashir T.","year":"2012","unstructured":"T. Bashir, C. Cloninger, N. Artinian, L. Anderson, A. Bernath, B. Holmes, A. Benavides-Serrato, N. Sabha, R. N. Nishimura, A. Guha, J. Gera, Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLOS ONE 7, e47741 (2012).","journal-title":"PLOS ONE"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-07-2223","article-title":"mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor","volume":"67","author":"Masri J.","year":"2007","unstructured":"J. Masri, A. Bernath, J. Martin, O. D. Jo, R. Vartanian, A. Funk, J. Gera, mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67, 11712\u201311720 (2007).","journal-title":"Cancer Res."},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1158\/0008-5472.CAN-13-3627","article-title":"Combined SFK\/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression","volume":"74","author":"Yori J. L.","year":"2014","unstructured":"J. L. Yori, K. L. Lozada, D. D. Seachrist, J. D. Mosley, F. W. Abdul-Karim, C. N. Booth, C. A. Flask, R. A. Keri, Combined SFK\/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res. 74, 4762\u20134771 (2014).","journal-title":"Cancer Res."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2003-04-1038","article-title":"Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity","volume":"103","author":"Cussac D.","year":"2004","unstructured":"D. Cussac, C. Greenland, S. Roche, R.-Y. Bai, J. Duyster, S. W. Morris, G. Delsol, M. Allouche, B. Payrastre, Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103, 1464\u20131471 (2004).","journal-title":"Blood"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201000"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1101\/gad.279661.116","article-title":"Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival","volume":"30","author":"Smithson L. J.","year":"2016","unstructured":"L. J. Smithson, D. H. Gutmann, Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. Genes Dev. 30, 1383\u20131388 (2016).","journal-title":"Genes Dev."},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1002\/cncr.29422","article-title":"A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1\/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma","volume":"121","author":"Bendell J. C.","year":"2015","unstructured":"J. C. Bendell, R. K. Kelley, K. C. Shih, J. A. Grabowsky, E. Bergsland, S. Jones, T. Martin, J. R. Infante, P. S. Mischel, T. Matsutani, S. Xu, L. Wong, Y. Liu, X. Wu, D. S. Mortensen, R. Chopra, K. Hege, P. N. Munster, A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1\/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer 121, 3481\u20133490 (2015).","journal-title":"Cancer"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/bjc.2016.59","article-title":"A first in man, dose-finding study of the mTORC1\/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies","volume":"114","author":"Mateo J.","year":"2016","unstructured":"J. Mateo, D. Olmos, H. Dumez, S. Poondru, N. L. Samberg, S. Barr, J. M. Van Tornout, F. Jie, S. Sandhu, D. S. Tan, V. Moreno, P. M. LoRusso, S. B. Kaye, P. Sch\u00f6ffski, A first in man, dose-finding study of the mTORC1\/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br. J. Cancer 114, 889\u2013896 (2016).","journal-title":"Br. J. Cancer"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14529","article-title":"m-TOR inhibitors and their potential role in haematological malignancies","volume":"177","author":"Calimeri T.","year":"2017","unstructured":"T. Calimeri, A. J. M. Ferreri, m-TOR inhibitors and their potential role in haematological malignancies. Br. J. Haematol. 177, 684\u2013702 (2017).","journal-title":"Br. J. Haematol."},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"40002","DOI":"10.1074\/jbc.M111.297432","article-title":"Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62\/sequestosome 1","volume":"286","author":"Huang S.","year":"2011","unstructured":"S. Huang, Z. J. Yang, C. Yu, F. A. Sinicrope, Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62\/sequestosome 1. J. Biol. Chem. 286, 40002\u201340012 (2011).","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"35287","DOI":"10.1074\/jbc.M113.495986","article-title":"Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein","volume":"288","author":"Preuss E.","year":"2013","unstructured":"E. Preuss, M. Hugle, R. Reimann, M. Schlecht, S. Fulda, Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J. Biol. Chem. 288, 35287\u201335296 (2013).","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.O114.039586"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"Yang H.","year":"2013","unstructured":"H. Yang, H. Wang, C. S. Shivalila, A. W. Cheng, L. Shi, R. Jaenisch, One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering. Cell 153, 910\u2013918 (2013).","journal-title":"Cell"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1221"}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.aar3938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T19:00:13Z","timestamp":1704826813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.aar3938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,7]]}},"alternative-id":["10.1126\/sciadv.aar3938"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.aar3938","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]},"article-number":"eaar3938"}}